BEOVU in the Treatment of Dystrophy-related Macular Neovascular Degeneration

Benha University

Status and phase: Unknown; Phase 4

Conditions: Dystrophy, Retinal

Treatments: Drug: Brolucizumab-Dbll

Study type: Interventional

Funder types: Other

Identifiers

NCT04690062

Hamaky7

Details and patient eligibility

About

Dystrophy-Related macular neovascularization degeneration occur is a vision threatening condition.The investigators evaluate the efficacy of BEOVU intravitreal treatment.

Full description

Baseline ,and postoperative 1 ,6 and 12 months full ophthalmic examination was done.

Procedure included intravitreal injection of Brolucizumab (BEOVU®, Genen-tech, South Francisco, CA)

Enrollment: 20 estimated patients

Sex: All

Ages: 18 to 50 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Dystrophy-Related macular neovascularization degeneration

Exclusion criteria

• age related macular degeneration , other causes of macular neovascularization degeneration

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

20 participants in 1 patient group

BEOVU

Experimental group

Description:

Intravitreal injection of BEOVU 3 loading injections ( monthly) then every 3 months

Treatment:

Drug: Brolucizumab-Dbll